Chemotherapy drugs and concurrent complementary therapy

Published on 28/05/2015 by admin

Filed under Internal Medicine

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 4007 times

Appendix 2 Chemotherapy drugs and concurrent complementary therapy

Janet Schloss, ND, MNutrMed

image

image

image

image

image

image

image

image

image

image

image

image

image

image

image

image

image

image

image

image

image

image

image

image

image

General supplementation for chemotherapy

image

References

1. Frischer H., Ahmad T. Severe generalized glutathione reductase deficiency after antitumour chemotherapy with BCNU″[1,3-bis(chloroethyl)-1-nitrosourea]. J Lab Clin Med. 1977;89(5):1080-1091.

2. Osiecki H. Cancer: a nutritional/biochemical approach, 2nd edn. Brisbane: BioConcepts Publishing; 2003.

3. Braun L., Cohen M. Herbs and natural supplements, an evidence-based guide, 3rd edn. Sydney: Elsevier; 2005.

4. Salerno E. Pharmacology for health professionals. St Louis: Mosby; 1999.

5. Kurbacher C.M., et al. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. 1996;103(2):183-189.

6. Tsutani H., et al. Pharmacological studies of retinol palmitate and its clinical effect in patients with acute non-lymphocytic leukemia. Leuk Res. 1991;15(6):463-471.

7. Branda R.F., et al. Nutritional folate status influences the efficacy and toxicity of chemotherapy in rats. Blood. 1998;92(7):2471-2476.

8. Teicher B.A., et al. In vivo modulation of several anticancer agents by beta-carotene. Cancer Chemother Pharmacol. 1994;34(3):235-241.

9. Conklin A. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer. 2000;37(1):1-18.

10. Wietrzyk J., et al. Antiangiogenic and antitumour effects in vivo of genistein applied alone or combined with cyclophosphamide. Anticancer Res. 2001;21(6A):3893-3896.

11 Davis L., Kuttan G. Effect of Withania somnifera on cyclophosphamide-induced urotoxicity. Cancer Lett. 2000;148(1):9-17.

12. Badary O.A. Taurine attenuates Fanconi syndrome induced by ifosimide without compromising its anti-tumour activity. Oncol Res. 1998;10(7):355-360.

13. Mills S., Bone K. The essential guide to herbal safety. St Louis: Churchill Livingstone; 2005.

14. Heisler T., et al. Peptide YY and vitamin E inhibit hormone-sensitive and -insensitive breast cancer cells. J Surg Res. 2000;91(1):9-14.

15. Prasad K.N., et al. Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins. Nutr Cancer. 1994;22(3):233-245.

16. Prasad K.N., et al. High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy. J Am Coll Nutr. 1999;18(1):13-25.

17. Nakagawa Y., et al. Relationship between ascorbic acid and alpha-tocopherol during diquat-induced redox cycling in isolated rat hepatocytes. Biochem Pharmacol. 1991;25:42(4):883-888.

18. Fullerton S.A., et al. Induction of apoptosis in human prostatic cancer cells with beta-glucan (maitake mushroom rythrocytese). Mol Urol. 2000;4(1):7-13.

19. Georgian L., et al. The protective effect of vitamin A and vitamin C on the chromosome-damaging activity of CCNU. Morphol Embryol (Bucur). 1986;32(4):241-245.

20. Gadjeva V., et al. Spin labeled antioxidants protect bacteria against the toxicity of alkylating antitumor drug CCNU. Toxicol Lett. 2003;144(3):289-294.

21. Blasiak J., et al. Genotoxicity of streptozotocin in normal and cancer cells and its modulation by free radical scavengers. Cell Biol Toxicol. 2004;20(2):83-96.

22. Mahesh T., Menon V.P. Quercetin allievates oxidative stress in streptozotocin-induced diabetic rats. Phytother Res. 2004;18(2):123-127.

23. Yilmaz O., et al. Effects of alpha lipoic acid, ascorbic acid-6-palmitate, and fish oil on the gluthione, malonaldehyde, and fatty acid levels in rythrocytes of streptozotocin induced diabetic male rats. J Cell Biochem. 2002;86(3):530-539.

24. Jonas C.R., et al. Plasma antioxidant status after high dose chemotherapy: a randomised trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr. 2000;72(1):181-189.

25. Hoffman R., et al. Enhanced anti-proliferative action of busulphan by quercetin on the human leukaemia cell line K562. Br J Cancer. 1989;59(3):347-348.

26. Durken M., et al. Deteriorating free radical-trapping capacity and antioxidant status in plasma during bone marrow transplantation. Bone Marrow Transplant. 1995;15(5):757-762.

27. Beer T.M., et al. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am J Clin Oncol. 2004;27(5):535-541.

28. Wigington D.P., et al. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines. Anticancer Res. 2004;24(5A):2905-2912.

29. Trump D.L., et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol. 2004;89–90(1–5):519-526.

30. Johnson C.S., et al. Vitamin D-related therapies in prostate cancer. Cancer Metastasis Rev. 2002;21(2):147-158.

31. Saunders D.E., et al. Additive inhibition of RL95-2 endometrial carcinoma cell growth by carboplatin and 1,25 dihydroxyvitamin D3. Gynecol Oncol. 1993;51(2):155-159.

32. Meara D.J., et al. Role of calcium in modulation of toxicities due to cisplatin and its analogs: a histochemical approach. Anticancer Drugs. 1997;8(10):988-999.

33. Lovat P.E., et al. Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs. Int J Cancer. 2000;88(6):977-985.

34. Lissoni P., et al. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer. 1997;5(2):126-129.

35. Jung B., Ahmad N. Melatonin in cancer management: progress and promise. Cancer Res. 2006;66(20):9789-9793.

36. Ghielmini M., et al. Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer. Br J Cancer. 1999;80(7):1058-1061.

37. Antunes L.M., et al. Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose dependent study. Pharmacol Res. 2000;41(4):405-411.

38. Ali B.H., Al Moundhri M.S. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: some recent research. Food Chem Toxicol. 2006;44(8):1173-1183.

39. Pace A., et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 2003;21(5):927-931.

40. Weisman R.A., et al. Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism. Otolaryngol Head Neck Surg. 1998;118(5):597-602.

41. Kalemkerian G.P., et al. A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: an Eastern Cooperative Oncology Group Study. Cancer. 1998;83(6):1102-1108.

42. Melli G., et al. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol. 2008;214(2):276-284.

43. Bougnoux P. n-3 polyunsaturated fatty acids and cancer. Curr Opin Clin Nutr Metab Care. 1999;2(2):121-126.

44. Jakubowicz-Gil J., et al. The effect of quercetin on pro-apoptotic activity of cisplatin in HeLa cells. Biochem Pharmacol. 2005;69(9):1343-1350.

45. Francescato H.D., et al. Protective effect of quercetin on the evolution of cisplatin-induced acute tubular necrosis. Kidney Blood Press Res. 2004;27(3):148-158.

46. Sliwinski T., et al. Zinc salts differentially modulate DNA damage in normal and cancer cells. Cell Biol Int. 2009;33(4):542-547.

47. Lissoni P., et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemo-endocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer in patients in a poor clinical state. J Pineal Res. 1999;23(1):15-19.

48. Savarese D.M., et al. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 2003;29(6):501-513.

49. Anderson P.M., et al. Oral glutamine reduces the duration and severity of stomatitis after cancer chemotherapy. Cancer. 1998;83:1433-1439.

50. Buckley J.E., et al. Hypomagnesemia after cisplatin combination therapy. Arch Intern Med. 1982;144:2347.

51. Van de Loosdrecht A.A., et al. Seizures in a patient with disseminated testicular cancer due to cisplatin-induced hypomagnesaemia. Acta Oncol. 2000;39:239-240.

52. Sadzuka Y., et al. Modulation of cancer chemotherapy by green tea. Clin Cancer Res. 1998;4(1):153-156.

53. Sonnenbichler J., et al. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther. 1999;290(3):1375-1383.

54. Slavik M., et al. Changes in serum copper and zinc during treatment with anticancer drugs interfering with pyridoxal phosphate. Adv Exp Med Biol. 1989;258:235-242.

55. Radu L., et al. The combined action of thiotepa and lomustine cytostatics, of estradiol hormone and of vitamins E and A on Walker tumor chromatin structure. Rom J Endocrinol. 1993;31(3–4):149-153.

56. Lialiaris T., et al. Enhancement and attenuation of cytogenetic damage by vitamin C in cultured human lymphocytes exposed to thiotepa or L-ethionine. Cytogenet Cell Genet. 1987;44(4):209-214.

57. Studzinski G.P., et al. Potentiation by 1-alpha, 25 dihdroxyvitamin D3 of cytotoxicity to HL-60 cells produced by cytarabine and hydroxyurea. J Natl Cancer Inst. 1986;76(4):641-648.

58. Kim C.H. Increased expression of N-acetylglucosaminyltransferase-V in human hepatoma cells by retinoic acid and 1alpha,25-dihydroxyvitamin D3. Int J Biochem Cell Biol. 2004;36(11):2307-2319.

59. Makishima M., et al. Growth inhibition and differentiation induction in human monoblastic leukaemia cells by 1alpha-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea. Br J Cancer. 1998;77(1):33-39.

60. Vukelja S.J., et al. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med. 1989;111(8):688-689.

61. Fabian C.J., et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs. 1990;8(1):57-63.

62. Nagore E., et al. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):225-234.

63. Nakashima T., et al. Phase 1 study of concurrent radiotherapy with TS-1 and vitamin A (TAR therapy) for head and neck cancer. Gan To Kagaku Tyoho. 2005;32(6):803-807.

64. Lotz-Winter H. On the pharmacology of bromelain: an update with special regard to animal studies on dose-dependent effects. Planta Med. 1990;56(3):249-253.

65. Toffoli G., Cecchin E. Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy. [Review] J Chemother. 2004;16(Suppl 4):31-35.

66. Etienne M.C., et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. Br J Cancer. 2004;90(2):526-534.

67. Zhong X., et al. [Effects of quercetin on the proliferation and apoptosis in transplantation tumor of breast cancer in nude mice]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2003;34(3):439-442.

68. Koide T., et al. Influence of flavonoids on cell cycle phase as analyzed by flow-cytometry. Cancer Biother Radiopharm. 1997;12(2):111-115.

69. Yuan H., Zhang Z. Some factors affecting sister-chromatid differentiation (SCD) and sister-chromatid exchange (SCE) in Hordeum vulgare. Mutat Res. 1992;272(2):125-131.

70. Pyrhonen S., et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71(3):587-591.

71. Nagai Y., et al. Vitamin A, a useful biochemical modulator capable of preventing methotrexate damage during methotrexate treatment. Pharmacol Toxicol. 1993;73:69-74.

72. Fishman P., et al. Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptors. J Cell Physiol. 2000;183(3):393-398.

73. Ohana G., et al. Differential effect of adenosine on tumour and normal cell growth: focus on the A3 adenosine receptor. J Cell Physiol. 2001;186(1):19-23.

74. Navarro-Peran E., et al. Kinetics of the inhibition of bovine liver dihydrofolate reductase by tea catechins: origin of slow-binding inhibition and pH studies. Biochemistry. 2005;44(20):7512-7525.

75. Rovensky J., et al. The effects of Enterococcus faecium and selenium on methotrexate treatment in rat adjuvant-induced arthritis. Clin Dev Immunol. 2004;11(3–4):267-273.

76. Mivazono Y., et al. Oxidative stress contributes to methotrexate-induced small intestinal toxicity in rats. Scand J Gastroenterol. 2004;39(11):1119-1127.

77. Perez J.E., et al. High-dose alpha-tocopherol as a preventive of doxorubicin-induced alopecia. Cancer Treat Rep. 1986;70(10):1213-1214.

78. Shinozawa S., et al. Effect of high dose alpha-tocopherol and alpha-tocopherol pretreatment on adriamycin (doxocurbicin) induced toxicity and tissue distribution. Physiol Chem Med NMR. 1988;20(4):329-335.

79. Ripoll E.A., et al. Vitamin E enhances the chemotherapeutic effects of adriamycin on human prostatic carcinoma cells in vitro. J Urol. 1986;136(2):529-531.

80. Quiles J.L., et al. Antioxidant nutrients and adriamycin toxicity. Toxicology. 2002;180(1):79-95.

81. Versantvoort C.H., et al. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer. 1993;68(5):939-946.

82. Monti E., Sinha B.K. Antiproliferative effect of genistein and adriamycin against estrogen-dependent and -independent human breast cell carcinoma lines. Anticancer Res. 1994;14(3):1221-1223.

83. Conklin K.A. Coenzyme Q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther. 2005;4(2):110-130.

84. Dovinova I., et al. Combined effect of lipoic acid and doxorubicin in murine leukaemia. Neoplasma. 1999;46(4):237-241.

85. Mijares A., Lopez J.R. L-carnitine prevents increase in diastolic [Ca2+] induced by doxocurbicin in cardiac cells. Eur J Pharmacol. 2001;425(2):117-120.

86. Waldner R., et al. Effects of doxocuribicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. J Cancer Res Clin Oncol. 2006;132(2):121-128.

87. Yeh Y.C., et al. A standardized extract of Ginkgo biloba suppresses doxorubicin-induced oxidative stress and p53-mediated mitochondrial apoptosis in rat testes. Br J Pharmacol. 2009;156(1):48-61.

88. Hu Q., et al. Antimutagenicity of selenium-enriched rice on mice exposure to cyclophosphamide and mitomycin C. Cancer Lett. 2005;220(1):29-35.

89. Fuga L., et al. Vitamin B2 (riboflavin) and a mixture of vitamin B2 and C affects MMC efficiency in aerated media under irradiation. Anticancer Res. 2004;24(6):4031-4034.

90. Kammerer C., Getoff N. Synergistic effect of dehydroascorbic acid and mixtures with vitamin E and beta-carotene on mitomycin C efficiency under irradiation in vitro. In Vivo. 2004;18(6):795-798.

91. Krishnaia A.P., Sharma N.K..Ascorbic acid potentiates mitomycin C-induced micronuclei and sister chromatid exchanges in human peripheral blood lymphocytes in vitro. Teratog Carcinog Mutagen. 2003;(Suppl 1):99-112.

92. Undeger U., et al. The modulating effects of quercetin and rutin on the mitomycin C induced DNA damage. Toxicol Lett. 2004;151(1):143-149.

93. Kurita T., et al. A dosage design of mitomycin C tablets containing finely powdered green tea. Int J Pharm. 2004;275(1–2):279-283.

94. Niitsu N., Homma Y. Adenosine analogs as possible differentiation-inducing agents against acute myeloid leukemia. [Review] Leuk Lymphoma. 1999;34(3–4):261-271.

95. Rafi M.M., et al. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res. 2000;20(4):2653-2658.

96. Berger M., et al. Effect of thiocitic acid (alpha-lipoic acid) on the chemotherapeutic efficacy of cyclophosphamide and vincristine sulphate. Arzneimittelforschung. 1983;33(9):1286-1288.

97. Scifo C., et al. Resveratrol and propolis as necrosis or apoptosis inducers in human prostate carcinoma cells. Oncol Res. 2004;14(9):415-426.

98. Menendez J.A., et al. Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. Breast Cancer Res Treat. 2002;72(3):203-219.

99. Seidner D.L., et al. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005;3(4):358-369.

100. Nesbitt L.T. Minimizing complications from systemic glucocorticosteroid use. Dermatol Clin. 1995;13(4):925-939.

101. Ravina A., et al. Reversal of corticosteroid-induced diabetes mellitus with supplemental chromium. Diabet Med. 1999;16(2):164-167.

102. Thompson T.A., Wilding G. Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells. Mol Cancer Ther. 2003;2(8):797-803.

103. Jiang F., Wang Z. Identification and characterization of PLZF as a prostatic androgen-responsive gene. Prostate. 2004;59(4):426-435.

104. Kang Z., et al. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol. 2004;18(11):2633-2648.

105. Juniewicz P.E., et al. Effects of androgen and antiandrogen treatment on canine prostatic arginine esterase. Prostate. 1990;17(2):101-111.

106. Zhang J., et al. Indole-3-carbinol induces a G1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells. Cancer. 2003;98(11):2511-2520.

107. Mi Y., Zhang C. Toxic and hormonal effects of polychlorinated biphenyls on cultured testicular germ cells of embryonic chickens. Toxicol Lett. 2005;155(2):297-305.

108. Mathur P.P., Chattopadhyay S. Involvement of lysosomal enzymes in flutamide-induced stimulation of rat testis. Andrologia. 1982;14(2):171-176.

109. Diamond T., et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer. 1998;83(8):1561-1566.

110. Fau D., et al. Mechanism for the hepatotoxicity of the antiandrogen, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes. J Pharmacol Exp Ther. 1992;263(1):69-77.

111. Iynem A.H., et al. The effect of prostate cancer and antiandrogenic therapy on lipid peroxidation and antioxidant systems. Int Urol Nephrol. 2004;36(1):57-62.

112. Diamond T.H., et al. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol. 2004;172(2):529-532.

113. Hatano T., et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int. 2000;86(4):449-452.

114. Cemeli E., et al. Modulation by flavonoids of DNA damage induced by estrogen-like compounds. Environ Mol Mutagen. 2004;44(5):420-426.

115. Kitson T.M., et al. Interaction of sheep liver cytosolic aldehyde dehydrogenase with quercetin, resveratrol and diethylstilbestrol. Chem Biol Interact. 2001;130–132(1–3):57-69.

116. Gehm B.D., et al. Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. J Steroid Biochem Mol Biol. 2004;88(3):223-234.

117. Morris G.Z., et al. Resveratrol induces apoptosis in LNCaP cells and requires hydroxyl groups to decrease viability in LNCaP and DU 145 cells. Prostate. 2002;52(4):319-329.

118. Cho D.I., et al. Effects of resveratrol-related hydroxystilbenes on the nitric oxide production in macrophage cells: structural requirements and mechanism of action. Life Sci. 2002;71(17):2071-2082.

119. Karasek M., et al. Melatonin inhibits growth of diethylstilbestrol-induced prolactin-secreting pituitary tumor in vitro: possible involvement of nuclear RZR/ROR receptors. J Pineal Res. 2003;34(4):294-296.

120. Jones J.L., et al. Genistein inhibits tamoxifen effects on cell proliferation and cell cycle arrest in T47D breast cancer cells. Am Surg. 2002;68(6):575-577. discussion 577–578

121. Ju Y.H., et al. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 2002;62(9):2474-2477.

122. Ravindranath M.H., et al. Anticancer therapeutic potential of soy isoflavone, genistein. [Review] Adv Exp Med Biol. 2004;546:121-165.

123. Liu B., et al. Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumour prevention. Cancer Res. 2005;65(3):879-886.

124. Constantinou A.L., et al. The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. Eur J Cancer. 2005;41(4):647-654.

125. Herbal Medicine Research and Education Centre. Herbs used in menopause. Complementary Medicine. 2005;4(4):51.

126. Donnelly L.E., et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol. 2004;287(4):L774-L783.

127. Ma Z.S., et al. Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercetin treatment is associated with inhibition of angiogenesis and cellular proliferation. Int J Oncol. 2004;24(5):1297-1304.

128. Fujiki H., et al. Cancer prevention with green tea and monitoring by a new biomarker, hnRNP B1. [Review] Mutat Res. 2001;480–481:299-304.

129. Suganuma M., et al. Mechanisms of cancer prevention by tea polyphenols based on inhibition of TNF-alpha expression. Biofactors. 2000;13(1–4):67-72.

130. Suganuma M., et al. Combination cancer chemoprevention with green tea extract and sulindac shown in intestinal tumor formation in Min mice. J Cancer Res Clin Oncol. 2001;127(1):69-72.

131. Perumal S.S., et al. Combined efficacy of tamoxifen and coenzyme Q10 on the status of lipid peroxidation and antioxidants in DMBA induced breast cancer. Mol Cell Biochem. 2005;273(1–2):151-160.

132. Perumal S.S., et al. Augmented efficacy of tamoxifen in rat breast tumorigenesis when gavaged along with riboflavin, niacin, and CoQ10: effects on lipid peroxidation and antioxidants in mitochondria. Chem Biol Interact. 2005;152(1):49-58.

133. De Leo V., et al. Menopause, the cardiovascular risk factor homocysteine, and the effects of treatment. [Review] Treat Endocrinol. 2004;3(6):393-400.

134. Palomba S., et al. Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene. Hum Reprod. 2004;19(2):415-421.

135. Al Akoum M., et al. Synergistic cytotoxic effect of tamoxifen and black cohosh on MCF-7 and MDA-MB-231 human breast cancer cells: an in vitro study. Can J Physiol Pharmacol. 2007;85(11):1153-1159.

136. Rickard D.J., et al. Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors alpha and beta. J Cell Biochem. 2003;89(3):633-646.

137. Rliwinski L., et al. Differential effects of genistein, estradiol and raloxifene on rat osteoclasts in vitro. Pharmacol Rep. 2005;57(3):352-359.

138. Antoniucci D.M., et al. Vitamin D insufficiency does not affect bone mineral density response to raloxifene. J Clin Endocrinol Metab. 2005;90(8):4566-4572.

139. Hascalik S., et al. Effects of resveratrol, raloxifene, tibolone and conjugated equine estrogen on vaginal squamous cell maturation of ovariectomized rats. Gynecol Obstet Invest. 2005;60(4):186-191.

140. Celik O., et al. Magnetic resonance spectroscopic comparison of the effects of resveratrol (3,4′,5-trihydroxy stilbene) to conjugated equine estrogen, tibolone and raloxifene on ovariectomized rat brains. Eur J Obstet Gynecol Reprod Biol. 2005;120(1):73-79.

141. Fiorelli G., et al. Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol. 1999;71(5–6):223-230.

142. Paterson A.H. Evaluating bone mass and bone quality in patients with breast cancer. Clin Breast Cancer. 2005;5(Suppl 2):S41-S45.

143. Lindsay R., et al. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int. 2005;16(4):372-379.

144. Brodowska A. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes]. Ann Acad Med Stetin. 2003;49:111-130.

145. Day J.K., et al. Dietary genistein increased DMBA-induced mammary adenocarcinoma in wild-type, but not ER alpha KO, mice. Nutr Cancer. 2001;39(2):226-232.

146. Subakir S.B., et al. Oxidative stress, vitamin E and progestin breakthrough bleeding. Hum Reprod. 2000;15(Suppl 3):18-23.

147. Barnes J.F., et al. Effects of two continuous hormone therapy regimens on C-reactive protein and homocysteine. Menopause. 2005;12(1):92-98.

148. Meram I., et al. Trace elements and vitamin levels in menopausal women receiving hormone replacement therapy. Clin Exp Obstet Gynecol. 2003;30(1):32-34.

149. Sliutz G., et al. Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. Br J Cancer. 1996;74(2):172-177.

150. Panosyan E.H., et al. Deamination of glutamine is a prerequisite for optimal asparagines deamination by asparaginases in vivo (CCG-1961). Anticancer Res. 2004;24(2C):1121-1125.

151. Rotoli B.M., et al. Inhibition of glutamine synthetase triggers apoptosis in asparaginase-resistant cells. Cell Physiol Biochem. 2005;15(6):281-292.

152. Myszka H., et al. Synthesis and induction of apoptosis in B cell chronic leukemia by diosgenyl 2-amino-2-deoxy-beta-D-glucopyranoside hydrochloride and its derivatives. Carbohydr Res. 2003;338(2):133-141.

153. Liu J.D., et al. Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice. J Cell Biochem. 2001;83(4):631-642.

154. Reid J.M., et al. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res. 1999;5(8):2192-2197.

155. Menendez J.A., et al. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: relationship to lipid peroxidation and HER-2/neu expression. Oncol Rep. 2004;11(6):1241-1252.

156. Beer T.M., et al. Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. [Review] World J Urol. 2005;23(1):28-32.

157. Beer T.M., Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. [Review] Mol Cancer Ther. 2004;3(3):373-381.

158. Beer T.M., et al. Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma. Cancer. 2004;100(4):758-763.

159. Wynter M.P., et al. Effect of n-3 fatty acids on the antitumour effects of cytotoxic drugs. In Vivo. 2004;18(5):543-547.

160. Ghalaut P.S., et al. Serum vitamin E levels in patients of chronic myeloid leukaemia. J Assoc Physicians India. 1999;47(7):703-704.

161. Przybyszewski W.M., et al. Protection of L5178Y cells by vitamin E against acute hydroxyurea toxicity does not change the efficiency of ribonucleotide reductase-mediated hydroxyurea-induced cytotoxic events. Cancer Lett. 1987;34(3):337-344.

162. Malec J., et al. Hydroxyurea-induced toxic side-effects in animals and an attempt at reducing them with vitamins E and C. Neoplasma. 1989;36(4):427-435.

163. Makaroy A.A., et al. Zinc(II)-mediated inhibition of ribonuclease Sa by an N-hydroxyurea nucleotide and its basis. Biochem Biophys Res Commun. 2004;319(1):152-156.

164. Higgin J.J., et al. Zinc(II)-mediated inhibition of a ribonuclease by an N-hydroxyurea nucleotide. Bioorg Med Chem Lett. 2003;13(3):409-412.

165. Wong W.S., McLean A.E. Effects of phenolic antioxidants and flavonoids on DNA synthesis in rat liver, spleen, and testis in vitro. Toxicology. 1999;139(3):243-253.

166. Miknyoczki S.J., et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther. 2003;2(4):371-382.

167. Fakih M., et al. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. Clin Colorectal Cancer. 2005;5(2):132-135.

168. Cao S., et al. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res. 2004;10(7):2561-2569.

169. Yoshikawa M., et al. Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J Exp Ther Oncol. 2004;4(1):25-35.

170. Bremner I., et al. Control of selenium and cobalt deficiency in lambs by supplementation of oral anthelmintics. Vet Rec. 1988;123(9):217-218.

171. Pathak A.K., et al. Chemotherapy alone vs chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. J Am Coll Nutr. 2005;24(1):16-21.

172. Varma M.V., Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci. 2005;25(4–5):445-453.

173. Siewinski M., et al. Determination of cysteine peptidases-like activity and their inhibitors in the serum of patients with ovarian cancer treated by conventional chemotherapy and vitamin E. J Exp Ther Oncol. 2004;4(3):189-193.

174. Argyriiou A.A., et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology. 2005;64(1):26-31.

175. Choi J.S., et al. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm. 2004;57(2):313-318.

176. Taixiang W., et al. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. Cochrane Database Syst Rev. 1, 2005. CD004540

177. Reiter R.J., et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol. 2002;54(10):1299-1321.

178. Kinnula K., et al. Endogenous antioxidant enzymes and glutathione S-transferase in protection of mesothelioma cells against hydrogen peroxide and epirubicin toxicity. Br J Cancer. 1998;77(7):1097-1102.

179. Jarvinen K., et al. Antioxidant defense mechanisms of human mesothelioma and lung adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol. 2000;278(4):L696-L702.

180. Shinozawa S., et al. Protective effects of various drugs on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice and rats. Biol Pharm Bull. 1993;16(11):1114-1117.

181. Solaini G., et al. Inhibitory effects of several anthracyclines on mitochondrial respiration and coenzyme Q10 protection. Drugs Exp Clin Res. 1985;11(8):533-537.

182. Tarumoto T., et al. Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. Exp Hematol. 2004;32(4):375-381.

183. Vera J.C., et al. Colony-stimulating factors signal for increased transport of vitamin C in human host defense cells. Blood. 1998;91(7):2536-2546.

184. Higucki T., et al. Induction of differentiation of retinoic acid-resistant acute promyelocytic leukemia cells by the combination of all-trans retinoic acid and granulocyte colony-stimulating factor. Leuk Res. 2004;28(5):525-532.

185. Matsui W., et al. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia. Br J Haematol. 2005;128(6):853-862.

186. Ganser A., et al. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol. Ann Hematol. 1996;72(4):237-244.

187. Maurer A.B., et al. Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors. Br J Haematol. 1995;89(3):449-456.

188. Carcamo J.M., et al. Vitamin C inhibits granulocyte macrophage-colony-stimulating factor-inducing signaling pathways. Blood. 2002;99(9):3205-3212.

189. Vera J.C., et al. Colony-stimulating factors signal for increased transport of vitamin C in human host defense cells. Blood. 1998;91(7):2536-2546.

190. Tao Y.H., Yang Y. [Effects of vitamin A on the differentiation, maturation and functions of dendritic cells from cord blood]. Zhonghua Er Ke Za Zhi. 2004;42(5):340-343.

191. Hengesbach L.M., Hoag K.A. Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice. J Nutr. 2004;134(10):2653-2659.

192. Fishman P., et al. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res. 2001;269(2):230-236.

193. Faderl S., Estrov Z. Commentary: effect of flavonoids on normal and leukemic cells. Leuk Res. 2003;27(6):471-473.

194. Mogattash S., Lutton J.D. Leukemia cells and the cytokine network: therapeutic prospects. Exp Biol Med. 2004;229(2):121-137.

195. Neri S., et al. L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. Neuropsychobiology. 2003;47(2):94-97.

196. Gedlicka C., et al. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol. 2002;20(15):3359-3361.

197. Socinski M.A., et al. The evolving role of pemetrexed (Alimta) in lung cancer. [Review] Semin Oncol. 2005;32(2 Suppl 2):S16-S22.

198. Buddle L.S., Hanna N.H. Antimetabolites in the management of non-small cell lung cancer. [Review] Curr Treat Options Oncol. 2005;6(1):83-93.

199. Adjei A.A. Pharmacology and mechanism of action of pemetrexed. [Review] Clin Lung Cancer. 2004;5(Suppl 2):S51-S55.

200. Fossella F.V. Pemetrexed for treatment of advanced non-small cell lung cancer. [Review] Semin Oncol. 2004;31(1 Suppl 1):100-105.

201. Horstman M.G., et al. Separate mechanisms for procarbazine spermatotoxicity and anticancer activity. Cancer Res. 1987;47(6):1547-1550.

202. Fuggetta M.P., et al. In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. Melanoma Res. 2004;14(3):189-196.

203. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005;5(Suppl 1):S38-S48.

204. El-Bayoumy K., Sinha R. Molecular chemoprevention by selenium: a genomic approach. Mutat Res. 2005;591(1–2):224-236.